Catalyst Wire Dossier Catalyst Wire Dossier

Recombinant Erwinia asparaginase (JZP458)

asparaginase (Erwinia) JZP458
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Recombinant Erwinia asparaginase (JZP458), covering 2026-04-08 to 2026-04-08. Get the full timeline:

Most recent: Clinical Trial Update: Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia [Phase 2]

See pricing